Subscribe to RSS
Download PDF
DOI: 10.1055/a-2564-2186
Consideration of Pneumonectomy in the Era of Chemo-Immunotherapy in Resectable NSCLC
Funding None.
Introduction
Recently, there has been increasing evidence for the use of neo-adjuvant chemoimmunotherapy in patients with resectable lung cancer. We aimed to analyze the pneumonectomy rates in the recently published phase 3 trials (including CM 816, KN 671, AEGEAN, and NEO-TORCH)[1] [2] [3] [4] in patients with resectable NSCLC and compare them with historical data. In this paper, we highlight the changing total surgical and pneumonectomy rates in the era of chemo-immunotherapy in resectable nonsmall cell lung cancer (NSCLC) patients.
Ethical Approval
The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Publication of this editorial and accompanying figures was waived from patient consent according to the UCI ethics committee/institutional review board.
Publication History
Received: 24 January 2025
Accepted: 18 March 2025
Article published online:
21 April 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Forde PM, Spicer J, Lu S. et al; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022; 386 (21) 1973-1985
- 2 Wakelee H, Liberman M, Kato T. et al; KEYNOTE-671 Investigators. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 2023; 389 (06) 491-503
- 3 Heymach JV, Harpole D, Mitsudomi T. et al; AEGEAN Investigators. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 2023; 389 (18) 1672-1684
- 4 Lu S, Zhang W, Wu L. et al Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial. JAMA 2024; 331 (03) 201-211
- 5 Felip E, Rosell R, Maestre JA. et al; Spanish Lung Cancer Group. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010; 28 (19) 3138-3145
- 6 Scagliotti GV, Pastorino U, Vansteenkiste JF. et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012; 30 (02) 172-178
- 7 National Cancer Institute. . Surveillance, Epidemiology and End Results Program. Accessed April 20, 2022 at: https://seer.cancer.gov/data-software/documentation/seerstat/
- 8 Albain KS, Swann RS, Rusch VW. et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374 (9687) 379-386
- 9 Jones GD, Caso R, Tan KS. et al. Propensity-matched analysis demonstrates long-term risk of respiratory and cardiac mortality after pneumonectomy compared with lobectomy for lung cancer. Ann Surg 2022; 275 (04) 793-799
- 10 Spigel DR, Faivre-Finn C, Gray JE. et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022; 40 (12) 1301-1311